QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online February 23, 2005
doi: 10.1242/10.1242/jcs.01696

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Peiretti, F. Articles by Nalbone, G. Search for Related Content PubMed PubMed Citation Articles by Peiretti, F. Articles by Nalbone, G.

Proteasome inhibition activates the transport and the ectodomain shedding of TNF- receptors in human endothelial cells

INSERM UMR626, IFR125 IPHM, Faculté de Médecine, 27 Bd Jean Moulin, Marseilles 13385 Cedex 5, France

Author for correspondence (e-mail: franck.peiretti{at}medecine.univ-mrs.fr)

Accepted 30 December 2004

Binding of tumor necrosis factor- (TNF-) to its transmembrane receptors (TNFRs) mediates proinflammatory, apoptotic and survival responses in several cell types including vascular endothelial cells. Because ectodomain shedding of cell surface molecules can be modified by proteasome activity, we studied in human endothelial cells whether the TNF-–TNFRs axis can be regulated by the cleavage of their transmembrane forms in a proteasome-dependent manner. We show that proteasome inhibition increases the release of TNF- and TNFRs from human endothelial cells and decreases their cellular and cell surface expression. This phenomenon involves the transient activation of mitogen-activated protein kinase p42/p44 that triggers the dispersion of TNF- and TNFRs from their intracellular Golgi-complex-associated pool towards the plasma membrane. This results in their enhanced cleavage by TNF- converting enzyme (TACE) because it is reduced by synthetic metalloprotease inhibitors, recombinant TIMP-3 and by a dominant negative form of TACE. In the presence of TACE inhibitor, proteasome inhibition increases the cell surface expression of TNFRs and enhances the sensitivity of these cells to the proapoptotic effect of recombinant TNF-.

In conclusion, our data provide evidence that proteasome inhibitors increase TACE-dependent TNFR-shedding in endothelial cells, supporting the use of these molecules in inflammatory disorders. In association with TACE inhibitor, proteasome inhibitors increase the amount of TNFRs at the cell surface and enhance the sensitivity to the proapoptotic effect of TNF-, which might be of interest in the antitumor therapy.

Key words: Endothelial cells, TNF receptors, Ectodomain shedding, Proteasome, TACE

This article has been cited by other articles:

				M. Canault, A. S. Leroyer, F. Peiretti, G. Leseche, A. Tedgui, B. Bonardo, M.-C. Alessi, C. M. Boulanger, and G. Nalbone Microparticles of Human Atherosclerotic Plaques Enhance the Shedding of the Tumor Necrosis Factor-{alpha} Converting Enzyme/ADAM17 Substrates, Tumor Necrosis Factor and Tumor Necrosis Factor Receptor-1 Am. J. Pathol., November 1, 2007; 171(5): 1713 - 1723. [Abstract] [Full Text] [PDF]

				S. K. Chang, B. K. Arendt, J. R. Darce, X. Wu, and D. F. Jelinek A role for BLyS in the activation of innate immune cells Blood, October 15, 2006; 108(8): 2687 - 2694. [Abstract] [Full Text] [PDF]